Literature DB >> 25553169

Complete response to ethnylestradiol prolonged for almost two years in patients with castration-resistant prostate cancer.

Hiroshi Hongo1, Takeo Kosaka1, Mototsugu Oya1.   

Abstract

An 80-year-old man with an elevated prostate-specific antigen (PSA) level of 120 ng/mL) presented to the hospital in February 2011. A prostate needle biopsy was performed, and pathological examination revealed prostatic adenocarcinoma. The Gleason score was 4+5=9. Computed tomography revealed metastases of the pelvic lymph nodes. Combined androgen blockade was started. The PSA concentration decreased to 1.68 ng/mL, but started increasing again in August 2012 to 6.08 ng/mL. Although bicalutamide was discontinued due to antiandrogen withdrawal syndrome, the PSA concentration increased even more. The PSA concentration reached 21.62 ng/mL in September 2012, at which time ethnylestradiol was started. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2 years. To our knowledge, this is first case report describing a complete response to ethnylestradiol that lasted for almost 2 years in a patient with castration-resistant prostate cancer.

Entities:  

Year:  2014        PMID: 25553169      PMCID: PMC4277536          DOI: 10.5489/cuaj.2293

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  9 in total

1.  Carcinoma of prostate treated with oestrogens.

Authors:  J D FERGUSSON
Journal:  Lancet       Date:  1946-10-19       Impact factor: 79.321

Review 2.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

3.  Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients.

Authors:  Kouji Izumi; Yoshifumi Kadono; Takashi Shima; Hiroyuki Konaka; Atsushi Mizokami; Eitetsu Koh; Mikio Namiki
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

4.  Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.

Authors:  Prasenjit Dey; Philip Jonsson; Johan Hartman; Cecilia Williams; Anders Ström; Jan-Åke Gustafsson
Journal:  Mol Endocrinol       Date:  2012-10-01

5.  Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer.

Authors:  Akinori Minato; Naohiro Fujimoto; Tatsuhiko Kubo; Shuji Harada; Soichiro Akasaka; Tetsuro Matsumoto
Journal:  Med Oncol       Date:  2012-02-10       Impact factor: 3.064

Review 6.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; Filiberto Zattoni; Nicolas Mottet
Journal:  Eur Urol       Date:  2013-11-12       Impact factor: 20.096

Review 7.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

8.  Oestrogen in the treatment of prostatic carcinoma. What is the safe and effective dose of ethinyloestradiol?

Authors:  J W Langeveld; A A Lycklama à Nijeholt; U Jonas
Journal:  Br J Urol       Date:  1989-01

9.  Castration-resistant prostate cancer: AUA Guideline.

Authors:  Michael S Cookson; Bruce J Roth; Philipp Dahm; Christine Engstrom; Stephen J Freedland; Maha Hussain; Daniel W Lin; William T Lowrance; Mohammad Hassan Murad; William K Oh; David F Penson; Adam S Kibel
Journal:  J Urol       Date:  2013-05-09       Impact factor: 7.450

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.